Monte Rosa Therapeutics
GLUE
74 hedge funds and large institutions have $171M invested in Monte Rosa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 7 closing their positions.
320% more call options, than puts
Call options by funds: $374K | Put options by funds: $89K
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
9% more funds holding
Funds holding: 68 → 74 (+6)
4.59% less ownership
Funds ownership: 79.55% → 74.96% (-4.6%)
39% less capital invested
Capital invested by funds: $281M → $171M (-$110M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$13.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.65M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$4.54M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.49M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$1.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.25M |
| 3 |
Millennium Management
New York
|
-$658K |
| 4 |
EC
EntryPoint Capital
New York
|
-$112K |
| 5 |
AIG
American International Group
New York
|
-$107K |
GLUE Hedge Fund Activity: Q2 2024 in Review
74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2024, worth a combined $171M — down 39% from $281M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GLUE positions and 7 closed out — a net gain of 7 holders — while 33 added to existing stakes and 12 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $13.6M. The largest seller was Casdin Capital, cutting an estimated $1.27M.
- 74 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2024, up from 68 in Q1 2024.
- Funds reported $171M of Monte Rosa Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
- 14 funds opened new Monte Rosa Therapeutics positions in Q2 2024 and 7 closed out, a net change of +7 holders.
- The largest Monte Rosa Therapeutics buyer in Q2 2024 was Suvretta Capital Management, an estimated $13.6M added.
- The largest Monte Rosa Therapeutics seller in Q2 2024 was Casdin Capital, an estimated $1.27M sold.
Based on aggregated 13F filings for Q2 2024.